A corporate venture capital arm of a global generic manufacturer is headquartered in the UK. The firm can invest $200K-$5m to a round. The firm will participate in rounds for digital health companies at all stages, as early as seed and through later venture rounds. The firm is open to working with companies globally.

Within digital health, the firm is seeking companies that are in the prevention and adherence space as well as digital medical devices and big data analytics platforms that address chronic diseases (Diabetes, Obesity and Cardiovascular), respiratory diseases, oncology, consumer and mental health. Past investments in the space include a wearable nicotine delivery device with integrated software and data analytics component to aid in smoking cessation.

The firm prefers to work with management teams with a track record in the space and a strong business plan.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A China-based private equity firm with additional offices in Beijing, Shanghai, and Hong Kong with an affiliation to an established Silicon Valley-based investment firm has raised 10 funds to date. The firm invests across several sectors including healthcare. The firm is a full-spectrum investor and will invest from Series A to pre-IPO and PIPE. The firm may also consider buyout and add-on acquisition for its portfolio companies. The firm can invest up to US$100 million per company. Typical investments range from US$5-50 millions. In terms of geography, the firm is China focused, but is also interested in opportunities from US and Europe with a strong China angle.

The firm invests opportunistically in the Healthcare sector and considers each deal on a case-by-case basis. Sectors of interest include biopharma, medical devices and equipment, diagnostics, HCIT, and R&D services that have large market potential. The firm is agnostic to the stage of development. The firm will consider products in pre-clinical up to market approved products.

The firm invests in both private and public companies. The firm invests in Chinese companies as well as US- and Europe-based companies with a China angle.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global pharmaceutical company headquartered in Japan, with USA operations, is actively seeking global collaboration and in-licensing opportunities within the early-stage ecosystem to strengthen their pipeline.

The company is seeking innovative therapies with highest focus on the following: CNS diseases, autoimmune diseases, and diabetes/kidney diseases. The company’s pipeline covers other indications as well and the company may review such opportunities on a case-by-case basis. The company is open to all stages of development, and those who have passed PoC are considered most ideal. The company has a strong interest in excellent technologies in biologics, including therapeutic antibodies, vaccines, and nucleic acid drugs, as well as cell-based phenotypic screening models of CNS or skeletal muscle diseases for new drug discovery.

Currently, the company’s main research focus can be broken down into 3 main branches: (1) nucleic acid medicine, (2) vaccines, and (3) macrocyclic compounds. In terms of their first interest, the company is highly interested in novel nucleic acid delivery systems targeted CNS and skeletal muscle, particularly those that could enable successful delivery from the gut. In terms of vaccines, the company is looking for innovative vaccine platforms to strengthen their current pipeline, which targets a broad range of infectious diseases. The last area of interest involves macrocyclic compounds with peptide modifications that could increase their cell permeability and therapeutic potential.

The company seeks to work with management teams with strong scientific expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Silicon Valley-based venture capital firm works closely with major incubators globally, through which they are able to identify high-potential, disruptive technologies, but is also seeking opportunities outside of their network. The firm is actively investing in early-stage companies and generally participates in Series A to B financing rounds. The initial size of investment depends largely on the company’s stage of development. The firm seeks investments globally.

The firm will consider opportunities in therapeutics, diagnostics, and digital health/healthcare IT. The firm is most interested in data-centric and enterprise technologies. The firm is agnostic to subsector and indication, but the firm will generally avoid medical device companies and early-stage therapeutics companies (i.e. those that take longer than 18 months to commercialize), but the firm may consider derisked assets or those that have an accelerated pathway to commercialization. Within healthcare IT technologies, the firm would like to see revenue-generating companies with good consumer traction.

The firm invests in both publicly traded and privately-owned companies. The firm is an active investor and will directly engage in the growth of their portfolio companies through a number of value-ons, including brand building, international expansion, talent recruiting, operation and technical guidance, etc. The firm need not have a fully established management team prior to investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private investment firm based in Florida makes co-investments into early stage life science companies. The firm prefers to invest in Series A-B rounds, and does not make seed investments. The firm makes investments of up to $300,000 out of the firm’s own capital, and is also working with an international partner that makes investments of up to $30 million in medical devices. The firm invests in startups US-wide.

The firm invests broadly in the life sciences and will consider opportunities in therapeutics, devices, diagnostics, healthcare IT and life science tools. The firm’s partner org is focused on late stage opportunities in the electronic medical device sector and will invest up to $30 million in these opportunities, with an interest in opportunities in which this org can act as a manufacturing partner. In other sectors, the firm makes early stage investments in companies that have established proof of concept, and interests include orphan drugs, the microbiome, healthcare data science, tools and some devices.

The firm prefers to invest in companies that have already received a significant round of funding in the past. For data and healthcare IT companies, initial revenues are preferred. The firm focuses on opportunities that will provide a short path to exit. The firm takes an active role with portfolio companies, particularly in making strategic and market connections with partners in Asia.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in USA, China, and India currently manages a fund with $125 million and is actively seeking investment opportunities across a wide range of industries. A significant allocation of the fund is dedicated to healthcare investments, while the rest of the fund will focus on investing in automation/robotics companies and relations to healthcare. On average, the size of investment is $2.5M. The firm seeks opportunities that provide some degree of investment loss protection through strong intellectual property. The firm can participate anywhere from Seed to Series B. The firm is willing to both lead and co-invest in companies located around the globe, with a preference in US, China, and Germany. The firm plans to make 6-8 investments per year but is flexible. The firm is actively seeking new investment opportunities.

The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, Diagnostics, and Healthcare IT companies. The firm is open to all kinds of sectors and indications. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. The firm is strongly interested in medical devices and cardiovascular diseases. In terms of therapeutics, the firm will look at products of all stages from pre-clinical to phase III. Regarding medical devices and diagnostics, the firm will invest at any stage of development.

The firm will invest in privately held companies only. The firm has no specific requirements for the management team. The firm may take a board seat in applicable cases, but the firm prefers to have board observer rights in its portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Toronto-based life sciences venture capital firm with offices throughout USA and Canada manages over $250M and is currently investing from a new fund closed in 2017. The firm typically makes initial investments ranging from $2-$6 million of equity and looks to invest $8-$12 million over the lifetime of the investment. The firm expects to make 4-6 investments over the next 12 months.

The firm invests primarily in Therapeutics and Medical Devices, with selective investments in diagnostic imaging and Healthcare IT. The firm is looking for companies phase I and later that have at least some human proof-of-concept with either early human efficacy signs or very strong animal data coupled with human safety data.

The firm invests in companies throughout the United States and Canada. The firm does not look to take an active role on the management team but does look to take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.